Replies to post #110055 on Biotech Values

[DewDiligence]

After the Imclone blowup, I remember that Congress instructed the FDA to pay attention to Pharma press releases/speeches with regard to FDA communications and FDA was to report any deviations to the SEC.

Great idea, but FDA does not have the funds to carry it out.

Unless the SEC brings it to their attention, I doubt that FDA staffers would know or care about the behavior of corporate executives on investor webcasts.